nach oben

Schweizer Gastroenterologie

Erschienen in:

06.12.2022 | Originalien

Liver tests: what to measure and what to do when abnormal

verfasst von: Dr. Paraskevi Archanioti, Prof. Jean-François Dufour

Erschienen in: Schweizer Gastroenterologie | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Liver diseases are frequent and silent. Physicians have to look for them. To do this several tests are available. This article reviews how to use these different tests, in which sequence and how to interpret them in the clinical context.

Vorheriger Artikel Helicobacter pylori – Update 2022

Nächster Artikel Sphingosin-1-Phosphat-Rezeptor-Modulatoren bei Colitis ulcerosa – Game Changer oder einer unter vielen?

Pratt DS, Kaplan MM (2000) Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342:1266–1271CrossRef

Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P et al (2011) Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 43:1131–1138CrossRef

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM et al (2018) Guidelines on the management of abnormal liver blood tests. Gut 67:6–19CrossRef

Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR (2020) Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology 71:306–333CrossRef

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol 2021;75:659–89.

Balmer ML, Dufour JF (2011) Non-alcoholic steatohepatitis—from NAFLD to MAFLD. Ther Umsch 68:183–188CrossRef

Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y et al (2022) HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol 77:128–139CrossRef

Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q et al (2022) GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 75:541–549CrossRef

Dillon JF, Miller MH, Robinson EM, Hapca A, Rezaeihemami M, Weatherburn C et al (2019) Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care. J Hepatol 71:699–706CrossRef

10.

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A et al (2017) Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25:1054–1062.e5CrossRef

Titel: Liver tests: what to measure and what to do when abnormal
verfasst von: Dr. Paraskevi Archanioti
Prof. Jean-François Dufour
Publikationsdatum: 06.12.2022
Verlag: Springer Vienna
Erschienen in: Schweizer Gastroenterologie / Ausgabe 4/2022
Print ISSN: 2662-7140
Elektronische ISSN: 2662-7159
DOI: https://doi.org/10.1007/s43472-022-00085-z

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Helicobacter pylori – Update 2022

Sphingosin-1-Phosphat-Rezeptor-Modulatoren bei Colitis ulcerosa – Game Changer oder einer unter vielen?

Éditorial

Diagnostik und Therapie des Kolonkarzinoms

Editoriale

Editorial